Daflon Dosing
For hemorrhoids and chronic venous insufficiency, the standard dose of Daflon (micronized purified flavonoid fraction) is 1000 mg daily, administered as two 500 mg tablets per day. 1, 2, 3
Standard Dosing Regimen
Chronic Venous Insufficiency (CVI)
- Maintenance dose: 1000 mg daily (two 500 mg tablets), taken as a single daily dose or divided into two doses 2, 4, 5
- Duration: Treatment can be continued long-term; studies demonstrate safety and efficacy for up to 12 months of continuous administration 5
- Clinical improvement typically appears within the first 2 months, with approximately 50% of symptom reduction occurring by this timeframe 5
Hemorrhoidal Disease
Acute hemorrhoidal episodes:
- Initial phase (Days 1-4): 3000 mg daily (six 500 mg tablets), divided as 3 tablets twice daily 2
- Maintenance phase (Days 5-7): 2000 mg daily (four 500 mg tablets), divided as 2 tablets twice daily 2
- This intensive regimen significantly reduces the duration and intensity of acute symptoms compared to placebo 2
Chronic (recurrent) hemorrhoids:
- Standard dose: 1000 mg daily (two 500 mg tablets) for 60-83 days 2, 3
- In controlled trials, this regimen reduced frequency, duration, and severity of hemorrhoidal symptoms with 40% of patients experiencing acute attacks versus 70% with placebo 3
- Mean attack duration was 2.6 days versus 4.6 days with placebo 3
Administration Details
- Formulation: Each tablet contains 500 mg of micronized purified flavonoid fraction (90% diosmin, 10% hesperidin) 6, 2
- Timing: Can be taken once daily or divided into two doses; no specific food requirements mentioned 4, 5
- The micronization process (particles <2 micrometers) enhances absorption of diosmin 2
Duration of Treatment
- CVI: Long-term treatment is appropriate; studies demonstrate maintained efficacy and excellent safety profile for 12 months of continuous use 5, 7
- Acute hemorrhoids: 7-day intensive regimen as outlined above 2
- Chronic hemorrhoids: 60-83 days for symptom control 2
- Venous ulcers: 2-6 months in combination with compression therapy 2, 7
Safety and Tolerability
- Daflon has a tolerability profile similar to placebo in clinical trials 2
- Most frequently reported adverse events are gastrointestinal (gastralgia reported in approximately 3% of patients in long-term studies) 5
- Laboratory parameters remain stable during prolonged administration 5
- The product is suitable for vegans and does not contain common allergens (gluten, lactose, tree nuts, peanuts) 6
Important Clinical Considerations
Daflon is not FDA-approved in the United States but is available as a medical food product (Vasculera) containing 600 mg diosmin per tablet 6. The dosing for this formulation would need adjustment accordingly, though the FDA label does not specify exact dosing recommendations 6.
For venous ulcers, Daflon should be used as adjunctive therapy to standard management (compression and local treatment), not as monotherapy 2, 7. In advanced CVI stages, combination with compression treatment, sclerotherapy, or surgery may be appropriate 7.